PROMOTING ACCESS TO AFRICAN RESEARCH

Sahel Medical Journal

Log in or Register to get access to full text downloads.

Remember me or Register



DOWNLOAD FULL TEXT Open Access  DOWNLOAD FULL TEXT Subscription or Fee Access

Antiphospholipids antibodies and migraine

Y.W Nyandaiti, S.A Bwala, A.A Gadzama, W Gashua, D Bubokk

Abstract


Background: Antiphospholipids antibodies has been associated with non-thrombotic neurological conditions such as migraine. We set out to estimate the concentration of antiphospholipids antibody among patients with migraine and normal population. Methods: This is prospective case-control study of 158 subjects including 82 migraine patients who fulfilled the International Headache Society criteria for the diagnosis of migraine headache and 76 age and sex-matched controls who were mostly hospital staff and medical students. Blood samples
were taken for quantification of antiphospholipids antibodies.
Results: There were 28 males and 54 females among the migraine patients and 30 males and 46 females among the controls. Their mean ages were 28.8 + 8.4 years and 26.4 + 3.9 years, respectively. Migraine patients had increased level of aPL (lgG anti β2GP1) 27.76 + 14.47IU/ml compared to the normal healthy adults (21.43 + 9.4IU/ml) (p<0.05). Similarly, antiphospholipid antibodies was significantly elevated in migraine patients with aura compared to those without aura,
(2=0.037; p<0.05). The frequency of migraine attacks correlated positively with the concentration of lgG anti β2GP1; ( p<0.05).
Conclusion: We demonstrated increased serum level of lgG anti β2GP1 among migraine patients. The frequency of migraine attacks correlated positively with the concentration of lgG anti β2GP1.



http://dx.doi.org/10.4314/smj2.v12i2.55655
AJOL African Journals Online